InvestorsHub Logo
Followers 185
Posts 2462
Boards Moderated 0
Alias Born 02/10/2017

Re: None

Friday, 01/15/2021 7:05:50 AM

Friday, January 15, 2021 7:05:50 AM

Post# of 238
don't get scared or robbed for your shares.

I bought VTGN at .79 in December they did a raise at .92 it surged to $2.50 days later

company has many catalyst and hammers that are about to drop.

70 million in cash no debt commercial product hitting the market in 2022 massive revenue generator.

EVGN 52 week high & multi year high was made $6.49 yesterday.EVGN is going way higher!!

get ready for liftoff!

double digits are coming.

green friendly revenue generating weed killer product next year to rival Monsanto which makes from Roundup? In 2015, the company made nearly $4.76 billion in sales and $1.9 billion in gross profits ...

only 40 million shares insiders & institutions like ARKG (cathie Wood & cantor fitzgerald own close to 50% the shares. high demand and low supply for these shares savvy investors are accumulating.

if you sold your shares call the police you have been robbed.

EVGN is a wealth creator at these levels. has 1000% ROI in the next year. Cathie Wood from ARK ETF owns it gene editing AI platform across many industries including biotech, agriculture & industrial

Cathie Wood ARKG ETF she picked Beam EDIT PACB gene editing stocks this one is going to exponentially grow and scale in share price and the EVGN has applications for biotech green agriculture and cannabis markets. This has 1000% upside potential by the end of the year.

EVGN is a leading computational biology gene editing AI company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of our broadly applicable Computational Predictive Biology (CPB) platform.

EVGN Subsidiaries:
Evogene group supports independent entities focusing on a defined commercial field with an exclusive license to use our unique solution for product development.

4.Lavie Bio

Evogene to Participate in CRISPR-IL Consortium to Provide End-to-End Artificial Intelligence System for Genome-Editing.

Evogene's work in the consortium is expected to include the broadening of its artificial intelligence capabilities that are expected to extend the range of its GENErator AI solution (part of Evogene's CPB platform). Evogene's GENErator AI solution already includes computational capabilities directing "which" edit should be made to achieve a specific trait; and the capabilities developed within the framework of the consortium aim to improve "how" these edits are made.

Genome Stocks-Gene Editing.

$PACB 6.2 billion market cap
$BEAM 5.4 billion market cap
$CRSP 13 billion market cap
$EDIT 4.8 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.8 billion market cap
$BLUE 3.3 billion market cap
$BNGO 1.2 billion market cap
$EVGN 200 million market cap 35 million shares 45% owned by institutions & insiders

Day Range:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent EVGN News